drugset
drugset / Trial / NCT06693986

Adenovirus (RGDCRAdCOX2F)

NCT06693986 ↗

Phase 1 Recruiting 18 enrolled Masonic Cancer Center, University of Minnesota
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.

Timeline

Start
2024-12-27
Primary completion
2028-10-15
Completion
2029-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject RGDCRAdCOX2F Unknown 3e+10 unknown Other
Subject RGDCRAdCOX2F Unknown 3e+11 unknown Other
Subject RGDCRAdCOX2F Unknown 9e+11 unknown Other
Subject RGDCRAdCOX2F Unknown 3e+12 unknown Other

Indications

pancreatic adenocarcinoma